Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662745 | 1.00 | KDM4E (0.43) | KDM4EGLAGSK3AGSK3BF12 | |
| SCHEMBL300899 | 0.89 | CSNK2A1 (0.41) | KDM4EGSK3AGSK3BMAPTCYP1A2 | |
| SCHEMBL28298212 | 0.79 | MAPT (0.40) | GSK3AGSK3BMAPTGBA1CYP1A2 | |
| SCHEMBL28028866 | 0.79 | MAPT (0.40) | GSK3AGSK3BMAPTGBA1CYP1A2 | |
| SCHEMBL290812 | 0.71 | CSNK2A1 (0.72) | KDM4EGLAHSD17B10USP2LMNA | |
| SCHEMBL28298247 | 0.70 | POLB (0.60) | KDM4EGLAF12IKBKBCYP1A2 | |
| SCHEMBL300860 | 0.68 | KDM4E (0.46) | KDM4EGLAF12IKBKBCFTR | |
| SCHEMBL28298219 | 0.67 | GSK3A (0.36) | KDM4EGSK3AGSK3BMAPTGBA1 | |
| SCHEMBL28029215 | 0.67 | GSK3A (0.36) | KDM4EGSK3AGSK3BMAPTGBA1 | |
| SCHEMBL4053006 | 0.66 | CYP3A4 (0.57) | KDM4EIKBKBMAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679432-B | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2015-04-22 | — | — | CN | claimed |
| CN-102574849-A | Herbicidal compounds | SYNGENTA LTD | 2012-07-11 | — | — | CN | claimed |
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| CN-109846884-A | With TOR kinase inhibitor for treating cancer | 西格诺药品有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-105039520-A | Identification of gene expression profile as a predictive biomarker for lkb1 status | SIGNAL PHARM LLC | 2015-11-11 | — | — | CN | disclosed |
| CN-101679432-B | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2015-04-22 | — | — | CN | disclosed |
| CN-104271138-A | Treatment of cancer with tor kinase inhibitors | SIGNAL PHARM LLC | 2015-01-07 | — | — | CN | disclosed |
| CN-104271139-A | Treatment of cancer with tor kinase inhibitors | SIGNAL PHARM LLC | 2015-01-07 | — | — | CN | disclosed |
| CN-103857804-A | Identification of gene expression profiles as predictive biomarkers for LKB1 status | SIGNAL PHARM LLC | 2014-06-11 | — | — | CN | disclosed |
| US-8383634-B2 | Methods of treatment using heteroaryl compounds and compositions thereof | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| CN-102821767-A | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARM LLC | 2012-12-12 | — | — | CN | disclosed |
| CN-102574849-A | Herbicidal compounds | SYNGENTA LTD | 2012-07-11 | — | — | CN | disclosed |
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | SIGNAL PHARMACEUTICALS, LLC | 2011-09-15 | — | — | US | disclosed |
| US-7968556-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-06-28 | — | — | US | disclosed |
| CN-101679432-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2010-03-24 | — | — | CN | disclosed |
| EP-2078018-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224217-A1 | METHODS OF TREATMENT USING HETEROARYL COMPOUNDS AND COMPOSITIONS THEREOF | JAK2, CHEK2, PHKG1 | KDM4E 1690/4885GLA 2209/4885GSK3A 348/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | KDM4E 2069/4885GLA 2608/4885GSK3A 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.